Accuracy of COVID-19 rapid antigenic tests compared to RT-PCR in a student population: The StudyCov study.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 11 02 2021
revised: 06 05 2021
accepted: 27 05 2021
pubmed: 17 6 2021
medline: 18 9 2021
entrez: 16 6 2021
Statut: ppublish

Résumé

There is a lack of data evaluating performance of antigenic test (AT) for SARS-CoV-2 diagnosis (Ag-RDT) in clinical practice, especially in asymptomatic subjects. The main objective of this study was to evaluate the diagnostic performance of AT compared to Reverse Transcription Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2 diagnosis. StudyCov is a monocentric cross-sectional study. A SARS-CoV-2 screening facility was set up in the Bordeaux University health campus from October 28th to November 20th 2020. Students willing to have a RT-PCR test (ARGENE SARS-CoV-2 R-GENE, BioMérieux, France) for SARS-CoV-2 diagnosis were also offered the Abbott Panbio™ SARS-CoV-2 antigenic rapid test. All participants attending the screening facility with an AT in addition to RT-PCR and having signed an informed consent were included in the study. The main objective was to assess performance of AT as compared with RT-PCR in the recruited population. Secondary objectives dealt with the analysis of the main objective stratified by current symptoms and risk exposure. A sensitivity analysis with different RT-PCR cycle thresholds was included. RT-PCR and AT results were available for 692 subjects. Overall sensitivity and specificity of AT tests were respectively 63.5% (95% confidence interval (CI): 49.0 - 76.4) and 100% (95% CI: 99.4 - 100). In the asymptomatic sub-group, they were respectively 35.0% (95% CI: 15.4% - 59.2%) and 100% (95% CI: 99.3 - 100). This study shows the poor sensitivity of AT in asymptomatic subjects, specificity being however excellent. The performance results fall below the World Health Organization recommendation of 80% sensitivity and question using AT in general population, especially when asymptomatic.

Identifiants

pubmed: 34134035
pii: S1386-6532(21)00145-1
doi: 10.1016/j.jcv.2021.104878
pmc: PMC8178956
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104878

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Références

Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
J Clin Virol. 2020 Dec;133:104659
pubmed: 33160179
medRxiv. 2020 Nov 12;:
pubmed: 33173911

Auteurs

Thomas Ferté (T)

Univ. Bordeaux ISPED, Inserm Bordeaux Population Health Research Center UMR 1219, Inria BSO, team SISTM, F-33000 Bordeaux, France. Electronic address: thomas.ferte@u-bordeaux.fr.

Viviane Ramel (V)

Bordeaux Population Health Research Center, Inserm U1219, Université de Bordeaux, 146 rue Léo Saignat, 33076, F-33000, Bordeaux, France; Agence régionale de santé Nouvelle-Aquitaine, 103 bis rue de Belleville, F-33000 Bordeaux, France.

Charles Cazanave (C)

CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France; Université de Bordeaux, EA 3671, F-33000 Bordeaux, France.

Marie-Edith Lafon (ME)

CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France; de Bordeaux, UMR CNRS 5234, F-33000 Bordeaux, France.

Cécile Bébéar (C)

CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France; Université de Bordeaux, EA 3671, F-33000 Bordeaux, France.

Denis Malvy (D)

Bordeaux Population Health Research Center, Inserm U1219, Université de Bordeaux, 146 rue Léo Saignat, 33076, F-33000, Bordeaux, France; CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France.

Agnès Georges-Walryck (A)

CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France.

Patrick Dehail (P)

Bordeaux Population Health Research Center, Inserm U1219, Université de Bordeaux, 146 rue Léo Saignat, 33076, F-33000, Bordeaux, France; Agence régionale de santé Nouvelle-Aquitaine, 103 bis rue de Belleville, F-33000 Bordeaux, France; CHU de Bordeaux, Place Amélie Raba Léon, F-33000 Bordeaux, France. Electronic address: patrick.dehail@ars.sante.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH